Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY PNH and APPOINT-PNH Trials

Poster Presentation
© 2024 American Society of Hematology. All rights reserved.
Meeting: 2024 ASH® Annual Meeting
Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter: Antonio M Risitano, MD, PhD
Affiliation: AORN Moscati, Avellino, Italy; University of Naples Federico II, Naples, Italy; The Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation, Barcelona, Spain
Presentation Date: December 9, 2024
Abstract Number: 4079
Session: Session: 508. Bone Marrow Failure: Acquired: Poster III
Related content: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Poster Presentation
Abstract Number: 2327
Presenter: David Dingli, MD, PhD
Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date Presented: December 7, 2024
Poster Presentation
Abstract Number: 5012
Presenter: Shreyans Gandhi, MD, MBBS, DNB, FRCPath, MPhil, MRCP
Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date Presented: December 9, 2024

To access this content please accept the following declarations.

This content was selected by and is provided to you upon your unsolicited request courtesy of Novartis with permission of ASH®.